Venlafaxine Extended-Release

@article{Wellington2001VenlafaxineE,
  title={Venlafaxine Extended-Release},
  author={Keri David. Wellington and Caroline M. Perry},
  journal={CNS Drugs},
  year={2001},
  volume={15},
  pages={643-669}
}
SummaryAbstractVenlafaxine inhibits presynaptic reuptake of serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine). Venlafaxine extended-release (XR) has been investigated in patients with major depression and in patients with major depression with associated anxiety in randomised, double-blind, multicentre trials. A therapeutic response in patients with major depression was evident at week 2 of treatment with venlafaxine XR 75 to 225 mg/day in a placebo-controlled trial. By… 
Desvenlafaxine Extended Release
TLDR
In two of three well designed, 8-week clinical trials, desvenlafaxine ER 50 mg/day significantly improved depression at study end, as assessed by the 17-item Hamilton Rating Scale for Depression (primary endpoint), compared with placebo.
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
TLDR
Results of this study indicate that, when titrated rapidly to their maximum recommended doses, escitalopram is at least as effective as venlafaxine XR and significantly better tolerated and do not support the hypothesis that nonselective SRIs have greater efficacy than selective SRIs.
Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial.
  • L. A. V. van Kerkhoven, R. Laheij, J. Jansen
  • Medicine, Psychology
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2008
Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults
TLDR
A large proportion of older adults treated with venlafaxine experience orthostatic hypotension, putting them at risk for falls, and older patients prescribed venl Lafaxine, particularly at high doses, should be advised and counseled about these adverse effects.
Experience of the use of velaxin (venlafaxine) in anxious depression
  • N. A. Il’ina
  • Medicine, Psychology
    Neuroscience and Behavioral Physiology
  • 2009
TLDR
Velaxin was found to be safe at intermediate therapeutic doses and there were improvements in laboratory results characterizing patients' somatic status.
A Randomized, Double-Blind, Placebo-Controlled Study of Venlafaxine XR in Out-Patients With Tension-Type Headache
TLDR
Preliminary evidence is provided for the efficacy and safety of venlafaxine XR 150 mg/day in reducing the number of days with TTH and the primary efficacy variable was the decline in number of Days with headache.
Venlafaxine–Propafenone Interaction Resulting in Hallucinations and Psychomotor Agitation
TLDR
T careful evaluation of concomitant treatment with CYP2D6 or P-glycoprotein inhibitors (eg, propafenone) and, when possible, venlafaxine serum concentration monitoring is suggested to prevent the onset of clinical disturbances during venl Lafaxine treatment.
ORIGINAL ARTICLES—ALIMENTARY TRACT Effect of the Antidepressant Venlafaxine in Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Trial
TLDR
Treatment with the selective serotonin and norepinephrine reuptake inhibitor venlafaxine is not more effective than placebo in patients with functional dyspepsia.
Clinical drug-drug interactions: focus on venlafaxine
TLDR
A comprehensive overview of the pharmacokinetic- and pharmacodynamic-based drug interactions involving VEN is provided, particularly addressing their clinical relevance.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 110 REFERENCES
Venlafaxine Extended-Release
TLDR
Venlafaxine XR is the only antidepressant presently approved for, and shown to be effective, in the long term management of generalised anxiety disorder (i.e. ≤6 months) of GAD.
Venlafaxine. A review of its pharmacology and therapeutic potential in depression.
TLDR
Wider clinical experience is required to better characterise and confirm potential advantages of venlafaxine compared with other antidepressant agents, which may include a rapid onset of action and reduced propensity to cause anticholinergic effects and cardiotoxicity compared with tricyclic antidepressants.
Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression
  • L. Cunningham
  • Psychology, Medicine
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 1997
TLDR
It is indicated that venlafaxine XR is safe, effective, and well tolerated for the treatment of major depression at once-daily doses ranging from 75 to 150 mg.
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
TLDR
Remission rates were significantly higher with venlafaxine than with an SSRI and the difference between SSRIs and placebo reached significance at week 4, and were not dependent on any one study or the definition of remission.
Efficacy and Tolerability of Once-Daily Venlafaxine Extended Release (XR) in Outpatients With Major Depression
TLDR
Venlafaxine XR was significantly more effective than placebo beginning at Week 2 on the CGI Severity scale, at Week 3 on theHAM-D depressed mood item, and at Week 4 on the HAM-D and MADRS; this superiority was maintained through Week 8.
Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.
  • M. Thase
  • Medicine, Psychology
    The Journal of clinical psychiatry
  • 1998
TLDR
Concern about blood pressure effects should not deter first-line use of this effective antidepressant, although more extensive studies of patients with cardiovascular diseases are still necessary.
Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers
TLDR
The data suggest enhancement of transmission through postsynaptic 5-HT1A receptors by venlafaxine but not paroxetine, after only 3 h, which is thought to be a useful measure of 5- HT1A receptor function.
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
TLDR
Once-daily venlafaxine XR is effective and well tolerated for the treatment of major depression and concomitant anxiety and provides evidence for superiority over fluoxetine.
Safety and tolerance profile of venlafaxine
TLDR
The safely profile and patient acceptability of venlafaxine are comparable to those of third-generation antidepressants, and possibly better than those of first-generation agents.
...
1
2
3
4
5
...